Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Lympho-myeloid restricted early thymic progenitors (ETPs) are postulated to be the cell of origin for ETP leukemias, a therapy-resistant leukemia associated with frequent co-occurrence of EZH2 and RUNX1 inactivating mutations, and constitutively activating signaling pathway mutations. In a mouse model, we demonstrate that Ezh2 and Runx1 inactivation targeted to early lymphoid progenitors causes a marked expansion of pre-leukemic ETPs, showing transcriptional signatures characteristic of ETP leukemia. Addition of a RAS-signaling pathway mutation (Flt3-ITD) results in an aggressive leukemia co-expressing myeloid and lymphoid genes, which can be established and propagated in vivo by the expanded ETPs. Both mouse and human ETP leukemias show sensitivity to BET inhibition in vitro and in vivo, which reverses aberrant gene expression induced by Ezh2 inactivation.

Original publication




Journal article


Cancer Cell

Publication Date





274 - 291.e8


BET inhibition, EZH2, FLT3-ITD, RUNX1, early thymic progenitor leukemia, early thymic progenitors, leukemia propagating cells, leukemic stem cells, Animals, Core Binding Factor Alpha 2 Subunit, Enhancer of Zeste Homolog 2 Protein, Gene Expression Regulation, Leukemic, Leukemia, Myeloid, Acute, Mice, Knockout, Mutation, Myeloid Cells, Signal Transduction, Stem Cells